Switch to:
Also traded in: Austria, Germany, Mexico, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.02
SHPG's Cash-to-Debt is ranked lower than
99% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. SHPG: 0.02 )
Ranked among companies with meaningful Cash-to-Debt only.
SHPG' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01  Med: 1.26 Max: No Debt
Current: 0.02
Equity-to-Asset 0.45
SHPG's Equity-to-Asset is ranked lower than
76% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. SHPG: 0.45 )
Ranked among companies with meaningful Equity-to-Asset only.
SHPG' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.25  Med: 0.57 Max: 0.85
Current: 0.45
0.25
0.85
Interest Coverage 1.69
SHPG's Interest Coverage is ranked lower than
96% of the 453 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. SHPG: 1.69 )
Ranked among companies with meaningful Interest Coverage only.
SHPG' s Interest Coverage Range Over the Past 10 Years
Min: 1.69  Med: 27.36 Max: 55.13
Current: 1.69
1.69
55.13
Piotroski F-Score: 5
Altman Z-Score: 1.24
Beneish M-Score: -1.20
WACC vs ROIC
7.67%
3.04%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 7.25
SHPG's Operating Margin % is ranked higher than
78% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. SHPG: 7.25 )
Ranked among companies with meaningful Operating Margin % only.
SHPG' s Operating Margin % Range Over the Past 10 Years
Min: -56.61  Med: 22.5 Max: 35.13
Current: 7.25
-56.61
35.13
Net Margin % 2.54
SHPG's Net Margin % is ranked higher than
73% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. SHPG: 2.54 )
Ranked among companies with meaningful Net Margin % only.
SHPG' s Net Margin % Range Over the Past 10 Years
Min: -59.59  Med: 16.4 Max: 56.55
Current: 2.54
-59.59
56.55
ROE % 1.33
SHPG's ROE % is ranked higher than
76% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. SHPG: 1.33 )
Ranked among companies with meaningful ROE % only.
SHPG' s ROE % Range Over the Past 10 Years
Min: -90.17  Med: 17.69 Max: 49.41
Current: 1.33
-90.17
49.41
ROA % 0.58
SHPG's ROA % is ranked higher than
78% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. SHPG: 0.58 )
Ranked among companies with meaningful ROA % only.
SHPG' s ROA % Range Over the Past 10 Years
Min: -37.5  Med: 9.75 Max: 31.57
Current: 0.58
-37.5
31.57
ROC (Joel Greenblatt) % 12.04
SHPG's ROC (Joel Greenblatt) % is ranked higher than
83% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. SHPG: 12.04 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
SHPG' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -396.76  Med: 102.56 Max: 345.74
Current: 12.04
-396.76
345.74
3-Year Revenue Growth Rate 32.10
SHPG's 3-Year Revenue Growth Rate is ranked higher than
79% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. SHPG: 32.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
SHPG' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -0.8  Med: 12.95 Max: 32.1
Current: 32.1
-0.8
32.1
3-Year EBITDA Growth Rate 5.60
SHPG's 3-Year EBITDA Growth Rate is ranked higher than
56% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. SHPG: 5.60 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
SHPG' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -1.9  Med: 18.8 Max: 34.1
Current: 5.6
-1.9
34.1
3-Year EPS without NRI Growth Rate -25.60
SHPG's 3-Year EPS without NRI Growth Rate is ranked lower than
76% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. SHPG: -25.60 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
SHPG' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -25.6  Med: 30.4 Max: 68.8
Current: -25.6
-25.6
68.8
GuruFocus has detected 6 Warning Signs with Shire PLC $SHPG.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» SHPG's 30-Y Financials

Financials (Next Earnings Date: 2017-08-02 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

SHPG Guru Trades in Q2 2016

Tweedy Browne Global Value 6,803 sh (New)
Jeff Auxier 1,712 sh (New)
Mario Gabelli 5,874 sh (New)
Tweedy Browne 42,247 sh (New)
Third Avenue Management 47,840 sh (New)
Keeley Asset Management Corp 17,723 sh (New)
Jeremy Grantham 28,297 sh (New)
Daniel Loeb 950,000 sh (New)
Mairs and Power 182,790 sh (New)
Leon Cooperman 204,100 sh (New)
John Buckingham 19,575 sh (New)
Julian Robertson 120,554 sh (New)
Paul Singer 39,372 sh (New)
Steve Mandel 2,529,148 sh (New)
Andreas Halvorsen 1,162,787 sh (+788.51%)
Pioneer Investments 35,875 sh (+128.52%)
Murray Stahl 8,068 sh (+34.47%)
First Eagle Investment 56,549 sh (+20.24%)
Lee Ainslie 1,920 sh (+17.79%)
Ken Fisher 44,092 sh (+11.18%)
John Paulson 88,000 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 82,128 sh (unchged)
Jim Simons Sold Out
David Dreman 140 sh (-9.09%)
John Paulson 5,194,600 sh (-26.54%)
Steven Cohen 130,100 sh (-34.03%)
» More
Q3 2016

SHPG Guru Trades in Q3 2016

Lee Ainslie 570,907 sh (+29634.74%)
Ken Fisher 166,168 sh (+276.87%)
Leon Cooperman 356,484 sh (+74.66%)
Steven Cohen 224,900 sh (+72.87%)
Third Avenue Management 68,224 sh (+42.61%)
Tweedy Browne Global Value 6,803 sh (unchged)
Kyle Bass 110,000 sh (unchged)
John Paulson 60,000 sh (unchged)
Jeff Auxier 1,712 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 82,128 sh (unchged)
Jeremy Grantham Sold Out
Paul Singer Sold Out
John Buckingham 19,504 sh (-0.36%)
Keeley Asset Management Corp 17,322 sh (-2.26%)
David Dreman 134 sh (-4.29%)
Daniel Loeb 900,000 sh (-5.26%)
First Eagle Investment 53,037 sh (-6.21%)
Murray Stahl 7,267 sh (-9.93%)
John Paulson 4,667,800 sh (-10.14%)
Tweedy Browne 36,304 sh (-14.07%)
Steve Mandel 1,694,675 sh (-32.99%)
Andreas Halvorsen 764,762 sh (-34.23%)
Mairs and Power 119,577 sh (-34.58%)
Julian Robertson 78,154 sh (-35.17%)
Pioneer Investments 15,699 sh (-56.24%)
Mario Gabelli 1,242 sh (-78.86%)
» More
Q4 2016

SHPG Guru Trades in Q4 2016

Scott Black 9,560 sh (New)
Lee Ainslie 1,425,420 sh (+149.68%)
Steven Cohen 410,700 sh (+82.61%)
Leon Cooperman 447,307 sh (+25.48%)
Julian Robertson 95,454 sh (+22.14%)
Andreas Halvorsen 919,604 sh (+20.25%)
Keeley Asset Management Corp 19,886 sh (+14.80%)
Steve Mandel 1,904,306 sh (+12.37%)
John Buckingham 20,722 sh (+6.24%)
Tweedy Browne Global Value 6,803 sh (unchged)
Pioneer Investments 15,699 sh (unchged)
John Paulson 160,000 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 82,128 sh (unchged)
First Eagle Investment Sold Out
Daniel Loeb Sold Out
Mario Gabelli Sold Out
David Dreman Sold Out
Jeff Auxier 1,705 sh (-0.41%)
Third Avenue Management 67,805 sh (-0.61%)
Tweedy Browne 35,534 sh (-2.12%)
Ken Fisher 151,274 sh (-8.96%)
John Paulson 4,206,100 sh (-9.89%)
Murray Stahl 6,000 sh (-17.43%)
Mairs and Power 24,659 sh (-79.38%)
» More
Q1 2017

SHPG Guru Trades in Q1 2017

John Hussman 1,800 sh (New)
Mario Gabelli 5,992 sh (New)
Jim Simons 319,177 sh (New)
Larry Robbins 1,015,477 sh (New)
Jana Partners 544,698 sh (New)
John Buckingham 27,469 sh (+32.56%)
Scott Black 12,080 sh (+26.36%)
Lee Ainslie 1,619,477 sh (+13.61%)
Leon Cooperman 487,307 sh (+8.94%)
Third Avenue Management 69,507 sh (+2.51%)
Tweedy Browne Global Value 6,803 sh (unchged)
Pioneer Investments 15,699 sh (unchged)
Jeff Auxier 1,705 sh (unchged)
Murray Stahl 6,000 sh (unchged)
John Paulson 130,000 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 82,128 sh (unchged)
Julian Robertson Sold Out
Tweedy Browne 34,653 sh (-2.48%)
Ken Fisher 144,475 sh (-4.49%)
John Paulson 3,998,100 sh (-4.95%)
Steve Mandel 1,714,306 sh (-9.98%)
Andreas Halvorsen 785,765 sh (-14.55%)
Mairs and Power 18,987 sh (-23.00%)
Steven Cohen 144,750 sh (-64.76%)
» More
» Details

Insider Trades

Latest Guru Trades with SHPG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:BIIB, NAS:REGN, OTCPK:CSLLY, NAS:GILD, NAS:VRTX, OTCPK:ALIOY, NAS:INCY, NAS:ALXN, NAS:CELG, OTCPK:GIKLY, OTCPK:UCBJY, NAS:BMRN, OTCPK:NVZMF, OTCPK:GMXAY, OTCPK:NONOF, NAS:SGEN, NAS:JAZZ, NAS:ALKS, NAS:TSRO, NAS:ALNY » details
Traded in other countries:SHPG.Austria, S7E.Germany, SHPG N.Mexico, SHP.UK, SHPGF.USA,
Headquarter Location:Ireland
Shire PLC is a biotech company. The Company is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines for patients with rare diseases and other select conditions.

Shire is a diversified, Ireland-based specialty drug firm. Shire has grown primarily through mergers and acquisitions, including the Transkaryotic Therapies acquisition in 2005 that established its genetic disease business with Replagal and Elaprase, and the merger with New River in 2007 that brought full rights to neuroscience drug Vyvanse. Shire completed the acquisition of ViroPharma (genetic diseases) in 2014, NPS Pharma (internal medicine) in 2015, and Baxalta (hematology, immunology, and oncology) in 2016.

Guru Investment Theses on Shire PLC

Keeley All Cap Value Fund Comments on Shire - Jan 27, 2017

Given the volatile Health Care sector this quarter, the Fund’s position in Shire (NASDAQ:SHPG) was also a leading detractor. Headline risk regarding potential pharmaceutical price controls has impacted the stock. With continued synergies from its acquisition of Baxalta and trading at 11x earnings, we feel the stock remains quite attractive.



From the Keeley All Cap Value Fund fourth quarter 2016 commentary.







Check out Keeley Asset Management Corp latest stock trades

Top Ranked Articles about Shire PLC

Keeley All Cap Value Fund Comments on Shire Guru stock highlight
Given the volatile Health Care sector this quarter, the Fund’s position in Shire (NASDAQ:SHPG) was also a leading detractor. Headline risk regarding potential pharmaceutical price controls has impacted the stock. With continued synergies from its acquisition of Baxalta and trading at 11x earnings, we feel the stock remains quite attractive. Read more...
Third Avenue Value Fund Buys 2 Stocks and Adds to 2 Positions in Q4 Fund reveals its picks earlier than most
Third Avenue Management (Trades, Portfolio), a private investment firm founded by legendary value manager Martin Whitman (Trades, Portfolio), ends its quarter on Oct. 31 and revealed the fourth-quarter trades of its Third Avenue Value Fund in its recent letter. Read more...
Steve Mandel Buys Shire, Axes 6 Positions in 2nd Quarter Guru reports quarterly portfolio
Steve Mandel (Trades, Portfolio), founder of Lone Pine Capital, utilizes a long-short equity strategy to create long-term capital growth. During the second quarter, the fund manager bought Shire PLC (NASDAQ:SHPG), reduced three existing positions and eliminated three stakes. Read more...
Leon Cooperman's Omega Buys Netflix, Citigroup, Shire Investor said this year he was finding many undervalued stocks
Leon Cooperman (Trades, Portfolio)’s much-followed firm Omega Advisors added 25 new stocks from a wide variety of industries in the recent quarter. Read more...

Ratios

vs
industry
vs
history
PE Ratio 148.06
SHPG's PE Ratio is ranked lower than
83% of the 240 Companies
in the Global Biotechnology industry.

( Industry Median: 28.38 vs. SHPG: 148.06 )
Ranked among companies with meaningful PE Ratio only.
SHPG' s PE Ratio Range Over the Past 10 Years
Min: 12.4  Med: 27.07 Max: 161.29
Current: 148.06
12.4
161.29
Forward PE Ratio 12.36
SHPG's Forward PE Ratio is ranked higher than
84% of the 160 Companies
in the Global Biotechnology industry.

( Industry Median: 18.05 vs. SHPG: 12.36 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 84.61
SHPG's PE Ratio without NRI is ranked lower than
75% of the 234 Companies
in the Global Biotechnology industry.

( Industry Median: 29.63 vs. SHPG: 84.61 )
Ranked among companies with meaningful PE Ratio without NRI only.
SHPG' s PE Ratio without NRI Range Over the Past 10 Years
Min: 12.87  Med: 23.44 Max: 106.93
Current: 84.61
12.87
106.93
Price-to-Owner-Earnings 340.86
SHPG's Price-to-Owner-Earnings is ranked lower than
67% of the 138 Companies
in the Global Biotechnology industry.

( Industry Median: 35.58 vs. SHPG: 340.86 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
SHPG' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 11.33  Med: 24.62 Max: 362.3
Current: 340.86
11.33
362.3
PB Ratio 1.80
SHPG's PB Ratio is ranked higher than
78% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. SHPG: 1.80 )
Ranked among companies with meaningful PB Ratio only.
SHPG' s PB Ratio Range Over the Past 10 Years
Min: 1.7  Med: 5.48 Max: 14.19
Current: 1.8
1.7
14.19
PS Ratio 3.99
SHPG's PS Ratio is ranked higher than
75% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. SHPG: 3.99 )
Ranked among companies with meaningful PS Ratio only.
SHPG' s PS Ratio Range Over the Past 10 Years
Min: 2.25  Med: 4.61 Max: 9.27
Current: 3.99
2.25
9.27
Price-to-Free-Cash-Flow 216.35
SHPG's Price-to-Free-Cash-Flow is ranked lower than
99.99% of the 141 Companies
in the Global Biotechnology industry.

( Industry Median: 24.99 vs. SHPG: 216.35 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
SHPG' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 10.98  Med: 26.53 Max: 229.95
Current: 216.35
10.98
229.95
Price-to-Operating-Cash-Flow 19.29
SHPG's Price-to-Operating-Cash-Flow is ranked higher than
58% of the 191 Companies
in the Global Biotechnology industry.

( Industry Median: 21.01 vs. SHPG: 19.29 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
SHPG' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 7.66  Med: 17.46 Max: 27
Current: 19.29
7.66
27
EV-to-EBIT 81.14
SHPG's EV-to-EBIT is ranked lower than
88% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. SHPG: 81.14 )
Ranked among companies with meaningful EV-to-EBIT only.
SHPG' s EV-to-EBIT Range Over the Past 10 Years
Min: -14  Med: 17.35 Max: 173.7
Current: 81.14
-14
173.7
EV-to-EBITDA 21.27
SHPG's EV-to-EBITDA is ranked lower than
60% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. SHPG: 21.27 )
Ranked among companies with meaningful EV-to-EBITDA only.
SHPG' s EV-to-EBITDA Range Over the Past 10 Years
Min: -16.9  Med: 13.9 Max: 33.2
Current: 21.27
-16.9
33.2
PEG Ratio 6.81
SHPG's PEG Ratio is ranked lower than
82% of the 101 Companies
in the Global Biotechnology industry.

( Industry Median: 2.13 vs. SHPG: 6.81 )
Ranked among companies with meaningful PEG Ratio only.
SHPG' s PEG Ratio Range Over the Past 10 Years
Min: 0.47  Med: 1.13 Max: 4.7
Current: 6.81
0.47
4.7
Shiller PE Ratio 54.44
SHPG's Shiller PE Ratio is ranked lower than
51% of the 53 Companies
in the Global Biotechnology industry.

( Industry Median: 53.05 vs. SHPG: 54.44 )
Ranked among companies with meaningful Shiller PE Ratio only.
SHPG' s Shiller PE Ratio Range Over the Past 10 Years
Min: 43.42  Med: 99 Max: 469
Current: 54.44
43.42
469
Current Ratio 1.02
SHPG's Current Ratio is ranked lower than
88% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. SHPG: 1.02 )
Ranked among companies with meaningful Current Ratio only.
SHPG' s Current Ratio Range Over the Past 10 Years
Min: 0.52  Med: 1.69 Max: 7.43
Current: 1.02
0.52
7.43
Quick Ratio 0.54
SHPG's Quick Ratio is ranked lower than
92% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. SHPG: 0.54 )
Ranked among companies with meaningful Quick Ratio only.
SHPG' s Quick Ratio Range Over the Past 10 Years
Min: 0.4  Med: 1.47 Max: 7.07
Current: 0.54
0.4
7.07
Days Inventory 266.33
SHPG's Days Inventory is ranked lower than
84% of the 436 Companies
in the Global Biotechnology industry.

( Industry Median: 126.28 vs. SHPG: 266.33 )
Ranked among companies with meaningful Days Inventory only.
SHPG' s Days Inventory Range Over the Past 10 Years
Min: 126.5  Med: 189.11 Max: 246.01
Current: 266.33
126.5
246.01
Days Sales Outstanding 74.19
SHPG's Days Sales Outstanding is ranked lower than
67% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. SHPG: 74.19 )
Ranked among companies with meaningful Days Sales Outstanding only.
SHPG' s Days Sales Outstanding Range Over the Past 10 Years
Min: 47.71  Med: 69.72 Max: 83.8
Current: 74.19
47.71
83.8

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 0.49
SHPG's Dividend Yield % is ranked lower than
81% of the 212 Companies
in the Global Biotechnology industry.

( Industry Median: 1.05 vs. SHPG: 0.49 )
Ranked among companies with meaningful Dividend Yield % only.
SHPG' s Dividend Yield % Range Over the Past 10 Years
Min: 0.23  Med: 0.42 Max: 0.7
Current: 0.49
0.23
0.7
Dividend Payout Ratio 0.65
SHPG's Dividend Payout Ratio is ranked lower than
55% of the 128 Companies
in the Global Biotechnology industry.

( Industry Median: 0.31 vs. SHPG: 0.65 )
Ranked among companies with meaningful Dividend Payout Ratio only.
SHPG' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.04  Med: 0.1 Max: 0.35
Current: 0.65
0.04
0.35
3-Year Dividend Growth Rate 26.40
SHPG's 3-Year Dividend Growth Rate is ranked higher than
80% of the 88 Companies
in the Global Biotechnology industry.

( Industry Median: 7.70 vs. SHPG: 26.40 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
SHPG' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 15.65 Max: 57.8
Current: 26.4
0
57.8
Forward Dividend Yield % 0.49
SHPG's Forward Dividend Yield % is ranked lower than
65% of the 204 Companies
in the Global Biotechnology industry.

( Industry Median: 1.05 vs. SHPG: 0.49 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 1.19
SHPG's 5-Year Yield-on-Cost % is ranked lower than
58% of the 265 Companies
in the Global Biotechnology industry.

( Industry Median: 1.54 vs. SHPG: 1.19 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
SHPG' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.56  Med: 1.02 Max: 1.7
Current: 1.19
0.56
1.7
3-Year Average Share Buyback Ratio -14.80
SHPG's 3-Year Average Share Buyback Ratio is ranked lower than
61% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. SHPG: -14.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SHPG' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -50.3  Med: -2.15 Max: 0.4
Current: -14.8
-50.3
0.4

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.85
SHPG's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
71% of the 159 Companies
in the Global Biotechnology industry.

( Industry Median: 3.16 vs. SHPG: 1.85 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
SHPG' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.13  Med: 1.82 Max: 3.78
Current: 1.85
1.13
3.78
Price-to-Median-PS-Value 0.86
SHPG's Price-to-Median-PS-Value is ranked higher than
59% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. SHPG: 0.86 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
SHPG' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.53  Med: 0.95 Max: 2.72
Current: 0.86
0.53
2.72
Price-to-Peter-Lynch-Fair-Value 4.42
SHPG's Price-to-Peter-Lynch-Fair-Value is ranked lower than
73% of the 66 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. SHPG: 4.42 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
SHPG' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.54  Med: 1.36 Max: 4.35
Current: 4.42
0.54
4.35
Earnings Yield (Greenblatt) % 1.23
SHPG's Earnings Yield (Greenblatt) % is ranked higher than
72% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. SHPG: 1.23 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
SHPG' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.6  Med: 5.4 Max: 8.4
Current: 1.23
0.6
8.4
Forward Rate of Return (Yacktman) % 19.86
SHPG's Forward Rate of Return (Yacktman) % is ranked higher than
58% of the 128 Companies
in the Global Biotechnology industry.

( Industry Median: 16.45 vs. SHPG: 19.86 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
SHPG' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 1.5  Med: 2.4 Max: 29
Current: 19.86
1.5
29

More Statistics

Revenue (TTM) (Mil) $13,260
EPS (TTM) $ 1.02
Beta1.72
Short Percentage of Float0.00%
52-Week Range $161.09 - 209.22
Shares Outstanding (Mil)302.37

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 15,274 16,466 17,648
EPS ($) 15.29 18.14 21.83
EPS without NRI ($) 15.29 18.14 21.83
EPS Growth Rate
(Future 3Y To 5Y Estimate)
10.03%
Dividends per Share ($) 1.09 1.20 2.09
» More Articles for SHPG

Headlines

Articles On GuruFocus.com
Shire to Participate at the Jefferies Healthcare Conference May 25 2017 
Shire Continues 20-Year Commitment to ADHD with New Research at 2017 Annual Meeting of American Psyc May 16 2017 
Shire and Parion Sciences Enter into a Collaborative License Agreement to Advance P-321 for Ophthalm May 01 2017 
Shire to Participate at the Deutsche Bank 42nd Annual Health Care Conference Apr 25 2017 
Shire Launches #PIPostsThanks Social Campaign to Raise Awareness of Primary Immunodeficiency (PI) Apr 24 2017 
Shire plc: Data Show A Bleeding Episode Occurs Every Three to 15 Seconds in People Living With Hemop Apr 17 2017 
INTUNIV® (Guanfacine Hydrochloride Prolonged Release), a Non-stimulant for the Treatment of ADHD, Mar 31 2017 
Andreas Halvorsen Buys Maker of First-in-Class Cancer Treatments, Calithera Biosciences Feb 22 2017 
Keeley All Cap Value Fund Comments on Shire Jan 27 2017 
KEELEY All Cap Value Fund 4th Quarter Commentary Jan 27 2017 

More From Other Websites
Why BioCryst Pharmaceuticals Stock Caught Fire Today May 25 2017
Shire to Participate at the Jefferies Healthcare Conference May 25 2017
Ultragenyx Receives Priority Review for rhGUS from FDA May 24 2017
Shire and tiny Lexington biotech say hemophilia drug trial misses mark May 22 2017
Shire (SHPG) Up on Positive Phase III Study Data on HAE Drug May 19 2017
Company News for May 19, 2017 May 19 2017
Blog Coverage: Shire's Stock Price Jumped on Positive Results in Hereditary Angioedema Treatment May 19 2017
Pharma Stock Roundup: J&J's Pharma Pipeline Update, Shire's HAE Data & More May 19 2017
Shire to Highlight New Research Into Chronic Hypoparathyroidism at the European Congress of... May 19 2017
Drugmaker Leads Industry Gains Thursday On Rare Disease Trial May 18 2017
[$$] Biotech Investor Clarus Ventures Raising $880 Million Fund May 18 2017
Shire's swelling disorder drug moves closer to U.S. approval May 18 2017
​Shire gains $2B in market cap as rare disease drug aces late-stage trial May 18 2017
The Lancet Publishes Phase 2 Results from Shire's Investigational Anti-MAdCAM Antibody Showing... May 18 2017
Shire ADRs jump almost 7% premarket after positive trial of Angioedema treatment May 18 2017
Shire's Investigational Treatment Lanadelumab Reduces Hereditary Angioedema Monthly Attack Rate by... May 18 2017
[$$] Health-Care Investor Agent Capital Seeks $100 Million Fund May 16 2017
Shire Continues 20-Year Commitment to ADHD with New Research at 2017 Annual Meeting of American... May 16 2017
ETFs with exposure to Shire Plc : May 15, 2017 May 15 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)